EUROPEAN
HEALTH FORUM
GASTEIN

von Rosenstiel, Philipp
Biogen



Philipp von Rosenstiel is Biogen’s Senior Director of Aducanumab studies. Philipp studied medicine in Munich and received his doctorate degree for his work on corticosteroids and hippocampal neurodegeneration at the Max-Planck Institute for Psychiatry and completed post-doctoral work at the Max-Delbrueck-Centre for Molecular Medicine in Berlin. Philipp has worked in the pharmaceutical industry for over 15 years with a focus on the clinical development of small molecules and biologics across all phases of development in adult and pediatric neurological indications. Since joining Biogen in 2014, Philipp led early clinical development of Biogen’s dementia portfolio before assuming responsibility for the clinical development of aducanumab.